Advertisement
Screener

Shattuck Labs, Inc. (STTK) EBITDA

Shattuck Labs, Inc. (STTK) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income -$16.16M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$15.54M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA (m); Operating income -$10.72M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$13.03M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2019-12-31 to 2025-12-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)-$16.16M(m)$0.00(m)(m)-$10.19M*(m)$11.70M(m)(m)
2026-03-31Reported(m)-$15.54M(m)$0.00(m)(m)-$13.42M(m)$10.95M(m)(m)
2025-09-30Reported(m)-$10.72M(m)$1.00M(m)$71.00K*-$8.93M*(m)$7.62M(m)(m)
2025-06-30Reported(m)-$13.03M(m)$0.00(m)(m)-$10.43M*(m)$8.68M(m)(m)
2025-03-31Reported(m)-$14.39M(m)$0.00(m)(m)-$12.03M(m)$9.92M(m)(m)
2024-09-30Reported(m)-$17.92M(m)$3.00M(m)$42.00K*-$16.07M*(m)$16.31M(m)(m)
2024-06-30Reported(m)-$22.96M(m)$1.61M(m)$17.00K*-$10.92M*(m)$19.24M(m)(m)
2024-03-31Reported(m)-$20.04M(m)$1.11M(m)$0.00-$16.16M(m)$16.26M(m)(m)
2023-09-30Reported(m)-$28.60M(m)$686.00K(m)$19.00K*-$16.73M*(m)$24.21M(m)(m)
2023-06-30Reported(m)-$22.75M(m)$200.00K(m)$296.00K*-$18.62M*(m)$18.20M(m)(m)
2023-03-31Reported(m)-$21.66M(m)$57.00K(m)$75.00K-$26.46M(m)$16.67M(m)(m)
2022-09-30Reported(m)-$25.23M(m)$212.00K(m)$750.00K*-$28.06M*(m)$18.86M(m)(m)
2022-06-30Reported(m)-$27.66M(m)$50.00K(m)$7.68M*-$16.32M*(m)$22.96M(m)(m)
2022-03-31Reported(m)-$24.17M(m)$0.00(m)$2.49M-$26.28M(m)$19.19M(m)(m)
2021-09-30Reported(m)-$17.58M(m)$1.90M(m)$964.00K*-$12.99M*(m)$15.14M(m)(m)
2021-06-30Reported(m)-$24.51M(m)-$4.23M(m)$2.33M*-$14.34M*(m)$14.88M(m)(m)
2021-03-31Reported(m)-$12.42M(m)$2.27M(m)$2.64M-$11.07M(m)$10.34M(m)(m)
2020-09-30Reported(m)-$11.84M(m)$2.44M(m)$99.00K*-$11.35M*(m)$11.80M(m)(m)
2020-06-30Reported(m)-$6.32M(m)$3.18M(m)$319.00K*$2.19M*(m)$7.75M(m)(m)
2020-03-31Reported(m)-$6.76M(m)$2.98M(m)$108.00K-$10.45M(m)$8.14M(m)(m)
2019-09-30Reported(m)-$7.53M(m)$1.78M(m)(m)(m)(m)$7.95M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$47.81M(m)(m)(m)-4780.80%$71.00K-$39.88M(m)$35.27M(m)$0.00
2024-12-31Reported-$76.77M(m)(m)(m)-1341.85%$59.00K-$60.52M(m)$67.21M(m)$0.00
2023-12-31Reported-$87.96M(m)(m)(m)-5308.21%$407.00K-$81.23M(m)$74.31M(m)$0.00
2022-12-31Reported-$100.23M(m)(m)(m)-15372.55%$11.61M-$94.50M(m)$82.90M(m)$0.00
2021-12-31Reported-$43.87M(m)(m)(m)-146.15%$7.93M-$57.12M(m)$56.56M(m)$0.00
2020-12-31Reported-$36.33M(m)(m)(m)-365.72%$727.00K-$33.66M(m)$37.48M(m)$0.00
2019-12-31Reported-$24.57M(m)(m)(m)-248.48%$470.00K-$20.98M(m)$29.22M(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03